An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. J of Skin. 2020;4(6):s73. doi:10.25251/skin.4.supp.73